Answers are grounded in this paper and cite their sources.
Introduction: Sorafenib is a multi-kinase inhibitor and decreases tumor cell proliferation. This study aimed to systematically review the existing evidence related to its cost-effectiveness. Methods and Results: EMBASE, MEDLINE, PUBMED, Google Scholar, and the Scopus database were searched and articles were selected on the basis of their correlation with the economic evaluations of Sorafenib. The quality of the selected studies was assessed using the Quality of Health Economic Studies instrument. This review revealed costs per quality-adjusted life years in the range of US $89,160 to $118,825, depending on whether the setting was first-line or second-line and which comparator is utilized. The results indicated that Sorafenib had not been considered as an appropriate treatment option for patients with metastasis Renal Cell Carcinoma (mRCC). Sorafenib was dominated (i.e. higher cost and lower efficacy) in comparison with Sunitinib in all cases. However, Sorafenib would be more cost-effective in comparison with bevacizumab plus interferon alfa in the treatment of mRCC. Conclusion: Sorafenib was more effective with higher cost than Best Supportive Care but Sorafenib was not cost-effective in view of current willingness to pay threshold.
No takes yet. Share an insight, caveat, or question.
Motevalli et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: